[Asia Economy Reporter Hwang Yoon-joo] Wellbiotech announced on the 17th that it has signed a sales contract for BTS Lenticular products worth 6.1 billion KRW. This accounts for 5.02% of recent sales revenue. The contract period is from May 16, 2022, to May 9, 2023.



This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing